Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health

Interest in psychedelic drugs for therapeutic purposes has re-emerged after decades of prohibition, and a recent trend within that broader revival is microdosing: ingesting very small, repeated doses of classic serotonergic psychedelics such as LSD or psilocybin. Earlier research and large online communities report that people try microdosing to enhance performance, mood, creativity or to relieve symptoms, but empirical studies remain few and mixed. Some controlled studies have found short-term or task-specific effects, while web-based surveys and qualitative reports have described perceived improvements in wellbeing alongside possible placebo influences and occasional adverse effects. Overall, the literature leaves unclear why individuals elect to microdose, how they approach it, and what subjective mental health or wellbeing changes they experience. Ryan and colleagues aimed to explore how people who microdose make sense of the practice, with particular attention to perceived effects on mental health and wellbeing. To allow in-depth understanding of subjective meaning, the investigators used anonymous, internet-based semi-structured interviews and analysed the material using Interpretative Phenomenological Analysis (IPA), a method designed to examine lived experience and meaning-making. The study took a neutral stance toward microdosing and focused on participants who were microdosing specifically to support mental health or wellbeing rather than for other motives.

The study used purposive sampling to recruit people who reported microdosing psychedelics with the intention of supporting their mental health or wellbeing. Recruitment adverts were posted on internet forums (notably Reddit, with lesser responses from The Shroomery and Bluelight). Participants contacted the researcher using non-identifying usernames; the researchers did not approach forum members directly. The extracted text indicates that inclusion and exclusion criteria were specified in a table, but those table details are not provided in the extracted material. It is stated that individuals microdosing for reasons other than mental health or wellbeing were excluded. Thirteen participants completed anonymous, live, text-based semi-structured interviews conducted via forum instant messaging or an optional end-to-end encrypted messenger. Because interviews were typed in real time they did not require transcription. The interview schedule covered reasons for microdosing, decisions to start, experiences of mental health and wellbeing, perceived benefits and disadvantages, and related topics; interviews were designed to allow participants time to reflect in writing and to reduce pressure. Safeguards for anonymity included requiring non-identifying usernames, avoiding collection of contact details, offering encrypted messaging, and a two-week data deletion key that was itself destroyed after that period so the link between username and interview was irreversibly removed. Participant characteristics reported in the extract: 13 people (10 male, 3 female), mean age 34.9 years, all educated to college level or above with over half holding undergraduate or postgraduate degrees, and all but one employed. Most microdosed LSD; one participant used both LSD and psilocybin. All participants except two (Kim and Isaac) reported prior experience of macrodoses of psychedelics. The analysis used IPA following Smith and colleagues' procedures. As part of analytic rigour, the researcher attended an IPA workshop group, received supervision to highlight bias, and kept a reflective diary; analysis followed the double-hermeneutic approach of interpreting participants' sense-making.

Thirteen participants contributed to three superordinate themes identified through IPA: 1) Seeking a solution: agency and rationale; 2) Microdosers as scientists; 3) Catalysing desirable and beneficial effects. All participants contributed to these themes. Theme 1 — Seeking a solution: agency and rationale: Participants generally described an intentional decision to try microdosing to address specific concerns—mental health problems (for some clinically diagnosed, for others self-identified), relationship or social difficulties, cognition, creativity or overall wellbeing. Several had tried conventional treatments (therapy, pharmaceuticals) before microdosing and framed microdosing as a deliberate, non-recreational attempt to help themselves. Prior experience with macrodoses of psychedelics or cannabis often informed the decision to microdose, though a minority (Kim and Isaac) had not previously taken macrodoses. Participants emphasised having a clear rationale for taking on the legal risks of using illegal substances. Theme 2 — Microdosers as scientists: Participants described researching microdosing, experimenting with schedules and doses, and monitoring effects in a regimented fashion. Many adopted established schedules (for example alternating dosing days) and then adjusted them individually; one participant described being “the rabbit in lab doing experiments on my brain.” Sensitivity to dose was commonly reported, and some participants distinguished immediate, day-of effects (lasting around 12 hours for some) from longer-term changes. Several acknowledged the possibility of placebo effects and some found it difficult to disentangle microdosing effects from concurrent supplements or lifestyle changes. Theme 3 — Catalysing desirable and beneficial effects: Participants typically framed microdosing not as a cure but as a catalyst or tool that facilitated learning, healthier behaviours and psychological change. Reported perceived benefits included affective improvements (10 participants discussed feeling more positive, less anxious, or reduced depressive symptoms), cognitive gains (improved focus, reduced rumination, clearer thinking), social benefits (greater confidence, improved relationships and reduced social anxiety), physical or behavioural benefits (reduced use of alcohol or stimulants, healthier behaviours reported by over half the sample), and creativity (reported by six participants). Adverse or undesirable effects were described but generally uncommon or mild: occasional increased anxiety or powerful emotions, sleep disturbance when dosing late, transient “cloudy head” or feeling slightly hungover, dose-related exuberance or talkativeness, and the legal risks of possession. Several participants emphasised that benefits sometimes diminished over subsequent days and that some of the longer-lasting changes could be attributable to lifestyle shifts initiated while microdosing or to prior macrodose experiences. Select participant verbatim excerpts included descriptions such as microdosing helping one person see life as “brighter again” and another likening their self-experimentation to being a “rabbit in lab.”

Ryan and colleagues interpret the findings as showing that people who microdose with the aim of supporting mental health and wellbeing tend to approach the practice deliberately and methodically, distinguishing their behaviour from recreational or impulsive drug use. The participants’ accounts are consistent with prior survey and qualitative work reporting perceived improvements in mood, anxiety, cognition and social functioning, and with reports that microdosers often seek performance or mood enhancement. The authors note that participants framed microdosing as a catalyst that enabled other changes—behavioural, cognitive and social—which may account for some sustained benefits rather than the pharmacological effects of microdoses alone. The discussion highlights several uncertainties and potential confounds identified by the investigators. Notably, many participants had earlier macrodose experience, raising the possibility that previous high-dose psychedelic sessions contributed to longer-term changes attributed to microdosing. The authors also acknowledge the potential for placebo effects and the challenge of separating microdose effects from concomitant supplements or lifestyle modifications. They compare their findings with previous studies (including those finding short-lived effects and those suggesting placebo influence) and suggest rational-choice frameworks may help explain the deliberate, controlled patterns of microdosing observed. Limitations the authors acknowledge include the text-based interview format that omits non-verbal cues (though it may reduce pressure and allow reflection), a sample recruited via internet forums that may over-represent educated, internet-active microdosers and those with positive experiences, and incomplete demographic detail due to anonymity safeguards. The small, purposive sample limits generalisability. For future research, the authors recommend larger and controlled studies, investigation of whether prior macrodose history influences outcomes, exploration of negative experiences and more work to establish whether unmet needs in formal healthcare are driving people to take legal risks to self-manage their mental health.

The investigators conclude that participants who microdose to support mental health and wellbeing reported approaching the practice with clear aims and a scientific, experimental mindset. They described sensitivity to dose, the ability to tailor regimes, and perceived benefits across mental health, social, cognitive and physical domains, while viewing microdosing principally as a catalyst for broader behavioural and psychological change rather than a stand-alone cure. The authors suggest these descriptive findings can guide larger, controlled studies—particularly to examine the role of prior macrodose experience, to capture negative as well as positive outcomes, and to determine whether people are microdosing because of gaps in existing healthcare provision. Understanding these issues is important given that psychedelic substances remain illegal in most jurisdictions and people are taking legal risks to self-manage their wellbeing.